MedTrace Logo

Cognitive Therapy for Recurrent Depression

NCT00118404 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 523

Last updated 2014-06-05

Study results available
· View outcomes & findings →

Summary

This study determined the effectiveness of continuation phase cognitive therapy versus antidepressant medication in preventing relapse of depression in people with recurrent depression.

Conditions

Interventions

BEHAVIORAL

Continuation phase cognitive therapy

Continuation phase cognitive therapy included 10 sessions over 8 months.

DRUG

Continuation phase fluoxetine

The dosage of fluoxetine was increased to 40 mg over 8 months.

OTHER

Continuation phase pill placebo

The dosage of pill placebo was increased to 40 mg over 8 months.

BEHAVIORAL

Acute phase cognitive therapy

For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Robin B. Jarrett, PhD · University of Texas, Southwestern Medical Center at Dallas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-03-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00118404 on ClinicalTrials.gov